Previous 10 | Next 10 |
Satsuma's lead and only candidate STS101 targeting treatment of acute migraines failed a pivotal trial in September last year. After a long silence, management has announced that it will launch a 2nd pivotal trial sometime in 2022, and has taken learnings from the 1st trial is confide...
Satsuma Pharmaceuticals ([[STSA]] +13.0%) agrees to sell 14,084,507 shares of its common stock to certain institutional investors in a private investment in public equity (‘PIPE’) financing.Gross proceeds from the PIPE to be ~$80M, based on the offering price of $5.68/share.Fina...
Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...
Satsuma Pharmaceuticals (STSA) shares jump nearly 25% premarket after the company announced plans of initiating a phase 3 trial for its STS101 (dihydroergotamine ((DHE)) nasal powder) migraine treatment in mid-2021, with topline results expected in the second half of 2022....
ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...
-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected to fund operations into second half of 2023- -Conference call this morning at 8:00...
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell 14,084,507 shares of its common stock to certain institutional investors in a private ...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional detai...
Satsuma Pharmaceuticals (STSA): Q3 GAAP EPS of -$0.69 beats by $0.02.Cash, cash equivalents and marketable securities of $82.1MPress Release For further details see: Satsuma Pharmaceuticals EPS beats by $0.02
Analysis of results from EMERGE ™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 C ash , cash equivalents and marketable securities of $ 82.1 million as of September 30 , ...
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...